olivLaw · US equity research
Azenta, Inc. AZTA
Special Industry Machinery, NEC · SIC 3559 · Vertical: Special Industry Machinery, NEC (SIC 3559)
Azenta, Inc. is a global provider of solutions for managing and storing biological samples for the life sciences industry, having exited its semiconductor business in 2022. The company is in a turnaround, with revenue rising in the third quarter of fiscal 2026 to 161 million USD, but with Multiomics and margins under pressure, so its trajectory remains one to watch.
At the close of 30 Oct 2026, Azenta, Inc. (AZTA) stock was 39.06 USD (−5.35% on the day), with market capitalisation 1.7 bn USD, dividend yield 0.26%, beta 1.40, 52-week range 16.02–42.73 USD. Latest reported quarter (Q3 2026): revenue of 161.2 m USD (+12.0% YoY), net income of 2.5 m USD, diluted EPS 0.05 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 57.4
- strong (55–70)
- Bollinger (20, 2)
- 33.33 – 41.88
- in the upper half of the band · %B 0.67 · band width 22.7%
- SMA 50 / 200
- 34.97 / 28.37
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 1.24 / 0.97
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +12.0% | −0.9% | +12.9 pp | — |
| 3 months | +38.9% | +1.2% | +37.6 pp | — |
| 6 months | +56.8% | +4.8% | +52.0 pp | — |
| Year to date | +17.4% | +10.7% | +6.7 pp | — |
| 1 year | +30.6% | +11.1% | +19.5 pp | +22.0% |
| 3 years | −14.1% | +80.7% | −94.8 pp | +19.3% |
| 5 years | −66.5% | +64.6% | −131.0 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 150.6 m | 147.4 m | 143.3 m | 143.9 m | 159.2 m | 148.6 m | 144.8 m | 161.2 m |
| Cost of revenue | 82.1 m | 78.6 m | 80.6 m | 77.5 m | 86.9 m | 84.9 m | 82.8 m | 88.8 m |
| Gross profit | 68.5 m | 68.8 m | 62.8 m | 66.4 m | 72.3 m | 63.7 m | 62.0 m | 72.4 m |
| Research & development | 7.5 m | 7.1 m | 7.6 m | 7.4 m | 8.3 m | 9.2 m | 9.4 m | 8.9 m |
| SG&A | 64.7 m | 70.0 m | 69.8 m | 60.1 m | 61.7 m | 60.6 m | 67.9 m | 67.2 m |
| Operating income | -4.6 m | -8.7 m | -18.2 m | -1.9 m | 1.9 m | -7.2 m | -165.8 m | -4.2 m |
| Depreciation & amortisation | 23.8 m | 18.1 m | 14.0 m ≈ | 14.7 m ≈ | 14.4 m | 13.6 m | 14.0 m ≈ | 13.6 m ≈ |
| Pre-tax income | 291.0 k | -3.2 m | -12.5 m | 2.3 m | 6.3 m | -2.1 m | -157.3 m | 846.0 k |
| Income tax | 2.0 m | 3.9 m | 7.2 m | 2.6 m | -45.4 m | 3.1 m | -323.0 k | 2.4 m |
| Net income | -6.6 m | -11.0 m | -47.7 m | -48.0 m | 50.9 m | -15.4 m | -160.8 m | 2.5 m |
| Diluted EPS | -0.14 | -0.25 | -1.04 | -1.05 | 1.11 | -0.34 | -3.49 | 0.05 |
| Operating cash flow | 17.7 m | 29.8 m | 14.4 m ≈ | 25.8 m ≈ | 2.2 m | 20.8 m | 13.5 m ≈ | 1.4 m ≈ |
| Capex | 9.4 m | 7.8 m | 7.4 m ≈ | 10.8 m ≈ | 7.9 m | 6.2 m | 7.4 m ≈ | 6.6 m ≈ |
| Share repurchases | 248.9 m | 0 | 0 ≈ | 0 ≈ | 0 | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | ⚠ 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 631.6 m | 334.2 m | 388.5 m | 513.7 m | 555.5 m | 551.5 m | 573.4 m | 593.8 m |
| Revenue YoY | +19.7% | — | +16.3% | +32.2% | +8.1% | −0.7% | +4.0% | +3.6% |
| Net income | 116.6 m | 437.4 m | 64.9 m | 110.7 m | 2.1 bn | -14.6 m | -164.9 m | -55.8 m |
| Net income YoY | +86.2% | — | −85.2% | +70.8% | +1,825.9% | −100.7% | unavailable | unavailable |
| Diluted EPS | 1.64 | 6.04 | 0.88 | 1.49 | 28.48 | -0.22 | -3.10 | -1.22 |
| Diluted EPS YoY | +84.3% | — | −85.4% | +69.3% | +1,811.4% | −100.8% | unavailable | unavailable |
| net % | 18.5% | 130.9% | 16.7% | 21.6% | 384.0% | -2.7% | -28.8% | -9.4% |
| Free cash flow | 61.2 m | 67.0 m | -2.1 m | 97.1 m | -539.5 m | -33.6 m | 12.4 m | 38.3 m |
The series breaks before 2019: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 30 Sept 2025
- Cash
- 279.8 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 1.7 bn USD
- Total assets
- 2.1 bn USD
- Debt / equity
- unavailable
- Current ratio
- 2.98x
- ROE
- -3.2%
- ROA
- -2.7%
- FCF margin
- 6.5%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 388.5 m | 513.7 m | 555.5 m | 551.5 m | 573.4 m | 593.8 m | SEC (XBRL)· 04 Dec 2025verified |
| Cost of revenue | 216.4 m | 269.9 m | 299.9 m | 312.3 m | 318.8 m | 323.5 m | SEC (XBRL)· 04 Dec 2025verified |
| Gross profit | 172.1 m | 243.8 m | 255.6 m | 239.2 m | 254.6 m | 270.3 m | SEC (XBRL)· 04 Dec 2025verified |
| Research & development | 17.8 m | 22.4 m | 27.5 m | 32.1 m | 31.5 m | 30.4 m | SEC (XBRL)· 04 Dec 2025verified |
| SG&A | 190.3 m | 252.1 m | 251.5 m | 263.7 m | 263.0 m | 261.6 m | SEC (XBRL)· 04 Dec 2025verified |
| Operating income | -36.6 m | -31.1 m | -24.7 m | -61.2 m | -51.3 m | -26.8 m | SEC (XBRL)· 04 Dec 2025verified |
| Depreciation & amortisation | 65.5 m | 65.3 m | 53.7 m | 85.6 m | 90.7 m | 61.2 m | SEC (XBRL)· 04 Dec 2025verified |
| EBITDA | 28.9 m ≈ | 34.2 m ≈ | 29.0 m ≈ | 24.3 m ≈ | 39.5 m ≈ | 34.4 m ≈ | SEC (XBRL)· 04 Dec 2025derived |
| Interest expense | 2.9 m | 2.0 m | 4.6 m | — | — | — | SEC (XBRL)· 25 Nov 2022verified |
| Pre-tax income | -40.3 m | -49.0 m | -9.9 m | -20.0 m | -19.1 m | -7.1 m | SEC (XBRL)· 04 Dec 2025verified |
| Income tax | -13.9 m | -20.1 m | 1.4 m | -12.0 m | 5.2 m | -31.6 m | SEC (XBRL)· 04 Dec 2025verified |
| Net income | 64.9 m | 110.7 m | 2.1 bn | -14.6 m | -164.9 m | -55.8 m | SEC (XBRL)· 04 Dec 2025verified |
| Diluted EPS | 0.88 | 1.49 | 28.48 | -0.22 | -3.10 | -1.22 | SEC (XBRL)· 04 Dec 2025verified |
| Weighted average diluted shares | 73.9 m | 74.5 m | 74.9 m | 66.3 m | 53.2 m | 45.9 m | SEC (XBRL)· 04 Dec 2025verified |
| Dividend per share | 0.40 | 0.40 | 0.10 | — | — | — | SEC (XBRL)· 25 Nov 2022verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 250.6 m | 227.4 m | 658.3 m | 649.5 m | 280.0 m | 279.8 m | SEC (XBRL)· 04 Dec 2025verified |
| Receivables | 94.8 m | 119.9 m | 163.8 m | 156.5 m | 154.2 m | 142.2 m | SEC (XBRL)· 04 Dec 2025verified |
| Inventories | 37.1 m | 60.4 m | 85.5 m | 128.2 m | 71.3 m | 75.0 m | SEC (XBRL)· 04 Dec 2025verified |
| Current assets | 649.5 m | 777.4 m | 2.5 bn | 1.4 bn | 833.0 m | 708.3 m | SEC (XBRL)· 04 Dec 2025verified |
| Goodwill | 453.2 m | 469.4 m | 513.6 m | 675.4 m | 691.4 m | 702.4 m | SEC (XBRL)· 04 Dec 2025verified |
| Intangibles (excl. goodwill) | 212.3 m | 186.5 m | 178.4 m | 294.3 m | 125.0 m | 101.8 m | SEC (XBRL)· 04 Dec 2025verified |
| Total assets | 1.6 bn | 1.8 bn | 3.7 bn | 2.9 bn | 2.1 bn | 2.1 bn | SEC (XBRL)· 04 Dec 2025verified |
| Accounts payable | 25.7 m | 42.4 m | 38.7 m | 35.8 m | 33.3 m | 37.7 m | SEC (XBRL)· 04 Dec 2025verified |
| Short-term debt | 827.0 k | — | — | — | — | — | SEC (XBRL)· 18 Nov 2020verified |
| Long-term debt | 49.6 m | 49.7 m | — | — | — | — | SEC (XBRL)· 24 Nov 2021verified |
| Current liabilities | 211.1 m | 345.1 m | 230.5 m | 210.9 m | 206.1 m | 237.7 m | SEC (XBRL)· 04 Dec 2025verified |
| Total liabilities | 345.7 m | 494.2 m | 352.7 m | 351.2 m | 332.4 m | 332.6 m | SEC (XBRL)· 04 Dec 2025verified |
| Equity | 1.2 bn | 1.3 bn | 3.4 bn | 2.5 bn | 1.8 bn † | 1.7 bn † | SEC (XBRL)· 04 Dec 2025verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 37.9 m | 149.9 m | -466.0 m | 5.8 m | 49.7 m | 72.2 m | SEC (XBRL)· 04 Dec 2025verified |
| Capex | 39.9 m | 52.8 m | 73.4 m | 39.4 m | 37.4 m | 33.9 m | SEC (XBRL)· 04 Dec 2025verified |
| Free cash flow | -2.1 m ≈ | 97.1 m ≈ | -539.5 m ≈ | -33.6 m ≈ | 12.4 m ≈ | 38.3 m ≈ | SEC (XBRL)· 04 Dec 2025derived |
| Investing cash flow | -22.7 m | -146.3 m | 1.5 bn | 431.4 m | 224.7 m | -90.5 m | SEC (XBRL)· 04 Dec 2025verified |
| Financing cash flow | -27.0 m | -25.9 m | -62.8 m | -840.5 m | -659.2 m | -9.6 m | SEC (XBRL)· 04 Dec 2025verified |
| Dividends paid | 29.5 m | 29.7 m | 7.5 m | 0 | 0 | — | SEC (XBRL)· 27 Nov 2024verified |
| Share repurchases | — | — | 0 | 838.5 m | 661.7 m | 0 | SEC (XBRL)· 04 Dec 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
Risk
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
30 Oct 2026Source: olivLaw, closing series
Market cap: 1.7 bn USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 1.31 – 1.77 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)1.31 – 1.77 (Mid 1.51)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -20.0% | 8 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 2.2% | 19 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 2.5x | 100 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 0.6% | 7 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | 2.9% | 42 (on a fixed band) | 19% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial19/100 · 1/2 factors with a value
- Quality· partial8/100 · 1/3 factors with a value
- Returns· partial42/100 · 1/2 factors with a value
- Valuation· partial7/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
AZENTA, INC. (AZTA). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 593.8 m USD in 2025; YoY growth 3.6%; net margin -20.0%; ROE -7.7%.
The estimated value range is 1.31–1.77 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 1.51 USD, the price of 39.06 USD leaves a potential of -96.1% (value / price − 1) and a margin of safety of -2,491.3% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 2.5x
What contradicts it
- Net margin: -20.0%
- Revenue CAGR 3Y: 2.2%
- FCF yield: 0.6%
- The price is above the estimated value range
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Payout ratio (FCF).
Versus the vertical median
Special Industry Machinery, NEC (SIC 3559) · same industry (4-digit SIC) · compared with 12 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LRCXLam Research Corporation | 298.7 bn | 35.6 | 70.1% | 32.3% | +26.0% | +52% / +306% |
| ACLSAxcelis Technologies Inc | 3.1 bn | 33.5 | 8.9% | 10.7% | −17.6% | +26% / −22% |
| VECOVeeco Instruments Inc | 2.4 bn | 108.5 | 2.6% | 3.4% | −7.4% | +35% / +62% |
| AZTAAzenta, Inc. | 1.7 bn | — | -7.7% | -20.0% | +3.6% | +31% / −14% |
| CRCTCricut, Inc. | 1.3 bn | 14.3 | 25.9% | 12.7% | −0.5% | +15% / −29% |
| ACMRACM Research, Inc. | 644.6 m | 21.5 | 10.6% | 14.5% | +15.2% | +10% / +234% |
| ERIIEnergy Recovery, Inc. | 355.3 m | 25.3 | 8.6% | 12.7% | −6.9% | −59% / −54% |
| ASYSAmtech Systems, Inc. | 223.2 m | 48.2 | 4.8% | 4.9% | −21.6% | +61% / +78% |
| VELOVelo3D, Inc. | 210.9 m | — | -61.5% | -89.6% | +12.1% | +18% / −99% |
| SOTKSono Tek Corp | 75.8 m | 38.4 | 10.1% | 9.3% | +2.0% | +6% / −4% |
| TRTTrio-Tech International | 50.6 m | — | -0.1% | -0.1% | +71.6% | +32% / +43% |
| CVVCvd Equipment Corporation | 27.2 m | 2.7 | 32.7% | 62.0% | −4.1% | +0% / −32% |
| ASMLAsml Holding NV | — | — | 50.5% | 29.4% | +15.6% | +48% / +162% |
1- and 3-year price returns: for AZTA from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Azenta, Inc. is a global provider of solutions for managing and storing biological samples for the life sciences industry, having exited its semiconductor business in 2022. The company is in a turnaround, with revenue rising in the third quarter of fiscal 2026 to 161 million USD, but with Multiomics and margins under pressure, so its trajectory remains one to watch.
SWOT
Strengths
- The company holds a leading position in biological sample management, a broad customer base and an integrated portfolio from procurement to data 1.
- Recurring revenue from storage and services provides stability, and revenue kept growing in the third quarter of fiscal 2026 3.
- Cash, equivalents and marketable securities are substantial, giving flexibility for investment and the share repurchase programme 3.
Weaknesses
- Gross and Adjusted EBITDA margins fell year over year in the third quarter, due to fixed-cost absorption and remediation work at automated stores 3.
- Free cash flow was negative in the third quarter, and the company is still recovering after periods of losses from discontinued operations 3.
- The company identified errors in previously issued financial statements, pointing to challenges in internal control over financial reporting 1.
Opportunities
- Integrating UK Biocentre could expand European capacity and attract customers in the United Kingdom and the region 2.
- Growth in cell and gene therapies could open additional demand for sequencing and gene synthesis services 1.
- Simplifying the portfolio after the B Medical Systems sale could focus resources on the most profitable segments 2.
Risks
- Multiomics organic declinehigh
Organic guidance for Multiomics has been lowered, and the segment could keep declining if demand for sequencing does not recover 3.
- Margin pressuremedium
Remediation costs and fixed-cost absorption have reduced gross margin, and these effects could persist if volumes stay low 3.
- Currency exposuremedium
A substantial share of cash is denominated in foreign currency, and exchange rate movements can affect reported results in US dollars 1.
- Dependence on research fundingmedium
Academic and government customers rely on public budgets, and cuts to these could affect sales 1.
- Compliance and security riskslow
Cybersecurity breaches, FDA rules and GLP standards could lead to penalties, delays or loss of contracts 1.
Investment thesis
What would need to be true (bull case)
- If SMS revenue keeps growing and the UK Biocentre integration goes to plan, the company could strengthen its position in biological sample storage 3.
- Exiting B Medical Systems and focusing on core segments could improve profitability over the medium term 2.
- Growth in cell and gene therapies could create durable demand for genomic and sample management services 1.
What would break the thesis
What to watch
- Fourth quarter results and delivery against fiscal 2026 revenue and Adjusted EBITDA guidanceQ4 2026
- Organic growth trend in Multiomics after the lowered guidanceQ4 2026
- Integration of UK Biocentre and its effect on Adjusted EBITDA margin2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Azenta provides biological and chemical compound sample exploration and management solutions to the life sciences industry, from research and clinical development through to commercialization 1. Founded in 1978 as Brooks Automation, the company sold its semiconductor businesses in February 2022 and has operated solely in life sciences since, renaming itself Azenta in December 2021 1. Its portfolio covers procurement, automated storage systems, genomic services, consumables, informatics software and sample repository services, organised into two reportable segments 1.
In fiscal 2025 revenue from continuing operations was 593.8 million USD, up 4% year over year, with a gross margin of 45.5% 1. The company agreed to sell B Medical Systems to simplify its portfolio, and the sale closed on July 1, 2026 for 63.0 million USD 2. In March 2026 Azenta acquired UK Biocentre Limited, a sample management provider in the United Kingdom, as a European operational hub 2.
The company had approximately 14,000 customers globally, including pharmaceutical and biotechnology companies, research hospitals, academic and government institutions and start-ups 1. Manufacturing is concentrated in Missouri in the United States and in the United Kingdom, and its genomic services network includes 14 laboratories, seven of them in the United States 1.
Market context
The market Azenta serves is linked to the growth of biologics, personalised medicine and cell and gene therapies, which have made biological samples critical assets in drug pipelines 1. The company describes a sizeable opportunity but notes that macroeconomic conditions, government research budgets and interest rates can cause customers to delay purchases 1. Its fiscal 2026 guidance of 613-618 million USD in revenue and flat to 1% organic growth points to an uncertain market 3.
Trends
- Cell and gene therapy growthtailwind
Growth in cell and gene therapies and personalised medicine raises the need for sample storage and sequencing, which could support demand for Azenta's services 1.
- Research budgets and interest ratesheadwind
Lower government research funding, higher interest rates and inflation could lead customers to delay purchases, reducing the company's sales 1.
- Acquisition-led consolidationmixed
The UK Biocentre acquisition expands European presence and integrated service capacity, but adds integration costs and dilutes Adjusted EBITDA margin 23.
- Regulation and complianceheadwind
Certain SMS products are regulated by the FDA and GLP services require laboratory accreditation, which could add compliance costs or delay launches 1.
Competitive position
In Sample Management Solutions the main competitors are Hamilton Company and Liconic AG for automation systems, and Laboratory Corporation of America Holdings and Thermo Fisher Scientific for storage, consumables and services 1. The company believes its integrated portfolio is unique, although each segment has its own specific competitors 1.
In Multiomics the competitors include BGI Genomics, Eurofins Scientific, GenScript Biotech, Integrated DNA Technologies, Novogene and Twist Bioscience, which offer sequencing and gene synthesis services 1. Competitive pressure in this segment is reflected in lower Sanger sequencing revenue 3.
- Hamilton Company
Competitor in automation systems for the SMS segment 1.
- Liconic AG
Competitor in automation systems for the SMS segment 1.
- Laboratory Corporation of America HoldingsLH
Competitor in storage, consumables and services for the SMS segment 1.
- Thermo Fisher ScientificTMO
Competitor in storage, consumables and services for the SMS segment 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- PE-Backed Robotics Firm Brooks Automation Said to Weigh IPOBloomberg Markets · 24 Jul 2026 · EN
The latest news item in our archive is from 24 Jul 2026; the newest SEC filing is from 30 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report30 Oct 2026Material agreement · Regulation FD disclosure · Other events
- Current report07 Oct 2026Exit or disposal costs · Material impairment · Financial statements and exhibits
- Current report17 Sept 2026Departure or appointment of officers · Financial statements and exhibits
- Current report04 Sept 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report24 Aug 2026Departure or appointment of officers · Regulation FD disclosure
- Current report11 Aug 2026Departure or appointment of officers · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report04 Aug 2026Results of operations · Financial statements and exhibits
- Current report08 Jul 2026Material agreement · Acquisition or disposition of assets · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report08 May 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-09-30 · SEC / Azenta, Inc. · 04 Dec 2025
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Azenta, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Azenta, Inc. · 04 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.